WeVote
Log In

Bill

Bill

HB 1489

Maryland Medical Assistance Program - Coverage for the Treatment of Obesity

2025 Regular Session Introduced by Tiffany Alston and 1 co-sponsor

HB 1489 expands Maryland Medicaid to cover obesity treatments including medications and clinical services for low-income residents.

Hearing 3/13 at 3:00 p.m.
0
WeVote Research Nonpartisan
Bill Summary · HB 1489

Legislative bill overview

HB 1489 would expand Maryland's Medical Assistance Program (Medicaid) to cover obesity treatment, including medications like GLP-1 agonists (e.g., semaglutide) and related clinical services. The bill aims to provide comprehensive obesity management to low-income Medicaid beneficiaries who currently lack coverage for these evidence-based treatments.

Why is this important

Obesity is a significant public health issue affecting healthcare costs and outcomes, yet many low-income individuals cannot afford effective treatments. Expanding Medicaid coverage would increase access to medications and services that clinical evidence supports, while potentially reducing costs from obesity-related complications like diabetes and heart disease. However, this also represents a substantial fiscal commitment during budget constraints.

Potential points of contention

  • Cost implications: GLP-1 medications are expensive; expanding coverage could significantly increase Medicaid expenditures, requiring budget reallocation or tax increases
  • Medical definition and scope: Determining which treatments qualify, appropriate eligibility criteria, and whether coverage includes behavioral therapy, surgery, or only pharmaceuticals
  • Equity and prioritization: Questions about whether Medicaid should cover weight-loss drugs when other medical needs remain underfunded, and whether this sets precedent for similar expansions

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.